Consolidated Statement Of Income

Kringle Pharma,Inc. - Filing #7290853

Concept 2023-10-01 to
2024-09-30
2023-10-01 to
2024-09-30
2023-10-01 to
2024-09-30
2023-10-01 to
2024-09-30
2022-10-01 to
2023-09-30
2022-10-01 to
2023-09-30
2022-10-01 to
2023-09-30
2022-10-01 to
2023-09-30
Consolidated statement of income
Statement of income
Net sales
80,038,000 JPY
69,250,000 JPY
Operating expenses
Selling, general and administrative expenses
897,920,000 JPY
958,012,000 JPY
Operating expenses
Operating profit (loss)
-817,882,000 JPY
-888,762,000 JPY
Operating expenses
Research and development expenses
643,266,000 JPY
716,792,000 JPY
Ordinary profit (loss)
-754,961,000 JPY
-852,660,000 JPY
Gross profit (loss)
80,038,000 JPY
69,250,000 JPY
Net sales
Selling, general and administrative expenses
Non-operating income
Interest income
10,000 JPY
5,000 JPY
Other
1,000 JPY
0 JPY
Non-operating income
62,920,000 JPY
43,431,000 JPY
Non-operating expenses
JPY
7,330,000 JPY
Non-operating expenses
Gross profit
Profit (loss) before income taxes
-754,961,000 JPY
-852,660,000 JPY
Income taxes - current
1,491,000 JPY
1,490,000 JPY
Income taxes
1,491,000 JPY
1,490,000 JPY
Profit (loss)
-756,453,000 JPY
-756,453,000 JPY
-756,453,000 JPY
-756,453,000 JPY
-854,151,000 JPY
-854,151,000 JPY
-854,151,000 JPY
-854,151,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.